{"id":135214,"date":"2022-10-27T04:15:49","date_gmt":"2022-10-27T08:15:49","guid":{"rendered":"https:\/\/44.250.171.167\/?p=135214"},"modified":"2022-10-31T00:34:33","modified_gmt":"2022-10-31T04:34:33","slug":"gland-pharma-limited-q2-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/gland-pharma-limited-q2-fy23-earnings-conference-call-insights\/","title":{"rendered":"Gland Pharma Limited Q2 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Gland Pharma Limited Q2 FY23 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/4X77Cs34eLo?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Gland Pharma Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/GLAND\/\">GLAND<\/a>) Q2 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>[00:02:23] GLAND said it saw improvement in supplies in 2H23 and have better visibility on key material supplies going forward.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:15:19] Neha Manpuria of BofA enquired about the US numbers, the pricing pressure and the growth going forward. Srinivas Sadu MD replied that vs. last year it remains flat. The EBITDA margin impact is most on the cost side impacting bottom line. From a growth perspective GLAND launched 7 products in 2Q23 and there\u2019s a plan to launch 11 in 3Q23 also.<\/li>\n<\/ul>\n<ul>\n<li>[00:17:06] Neha Manpuria from BofA enquired that with new product launches and less price erosion in US, why there was not much growth seen in the region QonQ. Srinivas Sadu MD clarified that some of the products, due to competition, GLAND couldn\u2019t get to the estimated volumes, especially oncology products like Pemetrexed and Bortezomib. GLAND expects to grow the existing base.<\/li>\n<\/ul>\n<ul>\n<li>[00:18:18] Neha Manpuria with BofA asked about RoW market going back to the last year levels and if it\u2019s a sustainable number. Srinivas Sadu MD answered that the pressure GLAND is facing with RoW and India is due to the cost disruptions. Also there are no one-offs. So once the cost settles down, GLAND believes it will have better opportunity to grow in the region.<\/li>\n<\/ul>\n<ul>\n<li>[00:19:34] Dheeresh of White Oak Capital asked about the profit share number for 2Q23 and share of new launches. Srinivas Sadu MD replied that the profit share is 7% and revenue from new launches is about 3%.<\/li>\n<\/ul>\n<ul>\n<li>[00:20:01] Dheeresh of White Oak Capital enquired about the reason for lower India business than the guided INR100 crore run rate. Srinivas Sadu MD answered that in India the import costs have not helped GLAND, resulting in margins being low. It\u2019s also due to the dollar going up, adding to increased cost and importing cost.<\/li>\n<\/ul>\n<ul>\n<li>[00:29:06] Sameer Baisiwala with Morgan Stanley enquired about the guidance in 1Q of 18-20% growth in topline for rest 9 months but it being flat in 2Q23 and also outlook for 2H23 on sales and margins. Srinivas Sadu MD replied that GLAND doesn\u2019t want to give guidance as the market is still volatile. On numbers, GLAND said insulin didn&#8217;t start at the beginning of the quarter and disruption in manufacturing as well as some delay in installations didn&#8217;t help in terms of capacities.<\/li>\n<\/ul>\n<ul>\n<li>[00:32:39] Ritesh Rathod of Nippon India asked about margin guidance, if the 31%, 32% margin excluding other income is intact. Srinivas Sadu MD said that excluding other income, margin for 2Q23 is 28.5%. GLAND expects it to be in that range on a QonQ basis.<\/li>\n<\/ul>\n<ul>\n<li>[00:41:15] Kartik Mehta from Klay Capital enquired about expense attributable to the CDMO business. Srinivas Sadu MD replied that at the EBITDA level it\u2019s INR15 crores in 2Q23, without including the depreciation. Adding depreciation it will be another INR6-7 crores for the quarter.<\/li>\n<\/ul>\n<ul>\n<li>[00:44:36] Rakesh Naidu of Motilal Oswal asked about Moody\u2019s downgrade. Srinivas Sadu MD answered that the issue is at the international level. GLAND\u2019s promoter is Fosun Pharma which is a listed company. There is no balance sheet linkage or dependency with them today. So there\u2019s no business impact.<\/li>\n<\/ul>\n<ul>\n<li>[00:49:08] Rakesh Naidu of Motilal Oswal enquired about the reason being slow on the INR300-350 crores of capex per annum. Srinivas Sadu MD said that it\u2019s a timing issue and it\u2019s all in track as these are approved projects. GLAND added that by year end it will end up with that number.<\/li>\n<\/ul>\n<ul>\n<li>[00:50:08] Saion Mukherjee with Nomura asked about profit share for 1H23 and FY23. Srinivas Sadu MD answered that for 1H23 and FY23 it\u2019s 8%.<\/li>\n<\/ul>\n<ul>\n<li>[00:50:56] Saion Mukherjee with Nomura enquired about China, how many products GLAND has filed and future plans. Srinivas Sadu MD said that the company has filed 8 products and two are expected approval by end of FY23; one each in 3Q and 4Q and 6 next year. GLAND has a filing plan for 6 products again in 2024.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Gland Pharma Limited (GLAND) Q2 FY23 Earnings Concall Management Update: [00:02:23] GLAND said it saw improvement in supplies in 2H23 and have better visibility on key material supplies going forward. Q&amp;A Highlights: [00:15:19] Neha Manpuria of BofA enquired about the US numbers, the pricing pressure and the growth going forward. Srinivas Sadu [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Gland Pharma Limited Q2 FY23 Earnings Conference Call Insights #GLAND #Q2 #FY23 #Earnings #Stocks","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-135214","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":139024,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-limited-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":135214,"position":0},"title":"Gland Pharma Limited Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"January 24, 2023","format":false,"excerpt":"Key highlights from Gland Pharma Limited (GLAND) Q3 FY23 Earnings Concall Management Update: [00:06:08] GLAND said the insulin line is in the process of ramping up post line improvements. The company expects to close Cenexi acquisition by March-April 2023 and focus on leveraging synergies between businesses. [00:06:24] GLAND also stated\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":131538,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-limited-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":135214,"position":1},"title":"Gland Pharma Limited Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"July 21, 2022","format":false,"excerpt":"https:\/\/youtu.be\/wKPiFWdsaFY Key highlights from Gland Pharma Limited (GLAND) Q1 FY23 Earnings Concall Management Update: GLAND said it is experiencing increased attrition and is ensuring the company builds enough resources, keeping in mind anticipated growth initiatives of the company. Q&A Highlights: Dheeresh Pathak from White Oak Capital asked about the profit\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":135226,"url":"https:\/\/alphastreet.com\/india\/glenmark-life-sciences-limited-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":135214,"position":2},"title":"Glenmark Life Sciences Limited Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"October 27, 2022","format":false,"excerpt":"https:\/\/youtu.be\/FHgUfHa30gw Key highlights from Glenmark Life Sciences Limited (GLS) Q2 FY23 Earnings Concall Management Update: [00:02:53] GLS said that the demand softness did not impact its business significantly due to the mid-volume and high-value products it offers. Q&A Highlights: [00:14:51] Neha Manpuria from Bank of America asked about the generic\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":132675,"url":"https:\/\/alphastreet.com\/india\/glenmark-life-sciences-limited-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":135214,"position":3},"title":"Glenmark Life Sciences Limited Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 9, 2022","format":false,"excerpt":"https:\/\/youtu.be\/02Igs_HUAfo Key highlights from Glenmark Life Sciences Limited (GLS) Q1 FY23 Earnings Concall Q&A Highlights: [00:14:56] Neha Manpuria from Bank of America asked about the generic API business, ex-COVID growth, how much of the growth is volume vs. pricing that has flown through. Yasir Rawjee MD replied that the growth\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":146646,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-gland-pharma-limited-for-q4-fy23\/","url_meta":{"origin":135214,"position":4},"title":"Earnings Summary Of Gland Pharma Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 18, 2023","format":false,"excerpt":"Gland Pharma Limited specializes in the production of sterile injectable formulations, including vials, ampoules, pre-filled syringes, and lyophilized products. The company's focus on sterile injectables positions it as a key player in critical care, oncology, ophthalmology, and other therapeutic areas. Gland Pharma's state-of-the-art manufacturing facilities adhere to international quality standards,\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":130476,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":135214,"position":5},"title":"Aurobindo Pharma Limited Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"June 6, 2022","format":false,"excerpt":"https:\/\/youtu.be\/ZZNGEHlRimc Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q4 FY22 Earnings Concall Management Update: AUROPHARMA received final approval for 3 ANDAs and launched 4 products in 4Q22. The company also filed 14 ANDAs, including 3 Injectables during 4Q. The total number of filings at the end of March \u201822 was\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/135214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=135214"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/135214\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=135214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=135214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=135214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}